

NUWIQ®

Antihemophilic Factor
(Recombinant)

“Since switching to NUWIQ, I almost forget what it’s like to deal with bleeds. That’s been my biggest takeaway: I no longer have to be slowed down a couple of days a month because of a breakthrough bleed.”



JEFF KUNKEL

Living Well with Severe Hemophilia A
Family • Career • Community

Disclaimer: The views and opinions expressed in this testimonial are those of the patient and do not necessarily reflect the opinions or recommendations of Octapharma USA. Results vary from patient to patient and treatment should be discussed with your HCP.

“I don’t have time to bleed!” That’s how Jeff Kunkel describes his busy and sometimes hectic lifestyle. Born and raised in Minnesota, Jeff is married with four children, three girls and one boy ranging in age from 2 to 12 years old. He also manages a busy grocery store, and is very active in the bleeding disorders community. Like many people with hemophilia A, Jeff was diagnosed shortly after birth.

“Growing up near Rochester, Minnesota, I’ve been fortunate to have the Mayo Clinic in my backyard—so I’ve received the best care—which is very important as my daughter also has mild hemophilia.”

Jeff is a big believer in preventative therapy, having started prophylaxis treatment 20 years ago when he was still in school. “I was on Helixate® FS for many years, and then later switched to Afstyla®. I was managing well for a while, but I was increasingly having breakthrough bleeds, despite being on prophylaxis. I needed something different.”

Working closely with his HTC team, Jeff decided that NUWIQ® prophylaxis was the right choice for him.

- Jeff is currently receiving NUWIQ on a 3 day-per-week prophylaxis schedule. “With my previous recombinant product, I would get three or four nosebleeds a week. Since I started NUWIQ prophylaxis, I haven’t had a single nosebleed—I’ve had no issue whatsoever.”
- Jeff says that the control and convenience he gets with NUWIQ really supports his active lifestyle, which he describes as *year-round*. “I like to be outside, spending time with my family when I’m not working. In the winter, we go sledding. In summertime, we go to the park and fish. NUWIQ really works well with my lifestyle. It’s very convenient, and it’s been keeping me bleed-free. It’s the best product I have ever used.”
- Jeff also reports that he has been very pleased with Octapharma’s Co-Pay Assistance Program. “Compared to my experience with other companies, it’s much more user friendly. That’s a make or break for somebody with a large family. To have a manufacturer that’s there when I need them—I think that’s huge.”

Indications and Usage

NUWIQ® is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and for routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ is not indicated for the treatment of von Willebrand Disease.

**Please see enclosed full Prescribing Information.
Please see other side for Important Safety Information.**

NUWIQ®

Antihemophilic Factor
(Recombinant)

Powerful Bleeding Control For Prophylaxis in Both Adults and Children

In Clinical Trials of Standard Prophylaxis with NUWIQ in Adults (N=32) and Children (N=59) Treated for 6 Months or Longer^{1*}



IN ADULTS

Median ABR for **All Bleeds** was **0.9**
50% had **zero** bleeding episodes
34% had **1** bleeding episode

IN CHILDREN

Median ABR for **All Bleeds** was **1.9**
34% had **zero** bleeding episodes
24% had **1** bleeding episode

ABR = annual bleeding rate.

*NUWIQ prophylaxis regimen: every other day or 3 times per week for ≥6 months.

NUWIQ Free Trial Program

- Eligible patients can receive up to **6 doses of NUWIQ** (not to exceed 20,000 IUs) at no cost
- NUWIQ is shipped directly to patients and administered under the direction and care of their physician

Co-Pay Assistance Program

- Up to \$12,000 per year savings on out-of-pocket treatment costs
- Patients must have commercial insurance or self-pay[†]
- Co-Pay assistance can only be applied to co-payments, deductibles, self-pay, and coinsurance associated with the cost of NUWIQ[‡]

[†]Patients with Medicare, Medicaid, Medigap, DoD TRICARE, or other federal or state government insurance are not eligible.

[‡]The Co-Pay Assistance Program does not cover costs associated with administration of therapy, such as office visits, infusion costs, or other professional services. The NUWIQ Co-Pay Assistance and Free Trial Programs are managed by a third-party program administrator.

Contraindications

NUWIQ® is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components. The most frequently occurring adverse reactions (>0.5%) in clinical trials were paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Please see enclosed full Prescribing Information.

Reference: 1. Products licensed in the U.S. to treat hemophilia. <https://www.hemophilia.org/sites/default/files/document/files/253Tables.pdf>.